Compare Nu Holdings Ltd (NU) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Nu Holdings Ltd trades at $15.58 (market cap $74.30B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Nu Holdings Ltd is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| NU | TAK | |
|---|---|---|
Market Cap | $74.30B | $58.74B |
Volume | 80,294,805 | 3,110,994 |
Sector | Financials | Health |
52-Week High | $18.76 | $19.05 |
52-Week Low | $11.60 | $13.23 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $96.91B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings (NU) trades at $15.58, down 0.51% on the day, as the Brazilian digital bank navigates market volatility. The stock shows strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Technical indicators are mixed with a bullish moving average signal but overbought RSI conditions. Recent news highlights acquisition speculation and Goldman Sachs' bullish $19 price target.
NU presents a compelling growth story with expanding profitability and analyst support, though risks include credit concentration and acquisition uncertainty. The stock trades near consensus targets with 57% buy ratings, suggesting moderate upside potential if execution continues.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
